Advertisement

Indian Journal of Surgical Oncology

, Volume 10, Supplement 1, pp 19–23 | Cite as

Treatment of Peritoneal Surface Malignancies with Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC): Experience in Israel

  • Almog Ben-Yaacov
  • Eran Nizri
  • Guy Lahat
  • Yaniv Berger
  • Eran Sadot
  • Ron Lavi
  • Dov Zippel
  • Gilbert Sebbag
  • Itzhak Avital
  • Aviad Hoffman
  • Mordechai Gutman
  • Ariel Halevy
  • Shlomo Schneibaum
  • Gur Ben-Ari
  • Daniel Benchimol
  • Joseph Klausner
  • Aviram NissanEmail author
  • For the Israeli Peritoneal Oncology Research Group
Original Article

Abstract

The treatment of peritoneal surface malignancies, either primary or secondary (peritoneal metastasis), has evolved over the past two decades. A nihilistic approach of incurable “carcinomatosis” is changing into treatment of peritoneal metastasis with curative intent. The aim of the present study is to review the current practice, past history, and future of peritoneal surface oncology in Israel. A systematic review of all patients treated in institutions performing cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy (HIPEC) for the treatment of peritoneal surface malignancies. Each center provided the following data: start year, number of total cases, number of cases performed in 2017, and the method used (open vs. closed technique). Between 1990 and 2018, there were 1462 patients treated by CRS/HIPEC in Israel by eight different surgical groups in six medical centers. Currently, there are seven surgical groups in six medical centers routinely performing CRS/HIPEC. The annual rate of CRS/HIPEC was 171 cases in 2017 with a range of (4–69 cases/center). This is the first step of establishing an Israeli Peritoneal Surface Oncology Group that will have joined database and perform clinical trials in this challenging field of surgical oncology.

Keywords

Cytoreductive surgery Hyperthermic intraperitoneal chemotherapy Peritoneal surface malignancy Multiple center experiance Experiance in Israel 

Notes

References

  1. 1.
    Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N, Cotte E, Gilly FN, Glehen O (2016) What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol 113(7):796–803CrossRefGoogle Scholar
  2. 2.
    Spratt JS, Adcock RA, Muskovin M, Sherrill W (1980) McKeown J. clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40(2):256–260Google Scholar
  3. 3.
    Sugarbaker PH (2003) Peritonectomy procedures. Surg Oncol Clin N Am 12:703–727CrossRefGoogle Scholar
  4. 4.
    Mehta SS, Bhatt A, Glehen O (2016) Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol 7(2):139–151CrossRefGoogle Scholar
  5. 5.
    Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456CrossRefGoogle Scholar
  6. 6.
    Verwaal VJ, Bruin S, Boot H et al (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2462–2432CrossRefGoogle Scholar
  7. 7.
    Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M (2013) Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 49(15):3140–3148CrossRefGoogle Scholar
  8. 8.
    van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240CrossRefGoogle Scholar
  9. 9.
    Zivanovic O, Sima CS, Iasonos A, Bell-McGuinn KM, Sabbatini PJ, Leitao MM, Levine DA, Gardner GJ, Barakat RR, Chi DS (2009) Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol 115(2):209–214CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2019

Authors and Affiliations

  • Almog Ben-Yaacov
    • 1
  • Eran Nizri
    • 2
  • Guy Lahat
    • 2
  • Yaniv Berger
    • 3
  • Eran Sadot
    • 4
  • Ron Lavi
    • 5
  • Dov Zippel
    • 1
  • Gilbert Sebbag
    • 6
  • Itzhak Avital
    • 6
  • Aviad Hoffman
    • 7
  • Mordechai Gutman
    • 3
  • Ariel Halevy
    • 5
  • Shlomo Schneibaum
    • 2
  • Gur Ben-Ari
    • 1
  • Daniel Benchimol
    • 4
  • Joseph Klausner
    • 2
  • Aviram Nissan
    • 1
    Email author
  • For the Israeli Peritoneal Oncology Research Group
  1. 1.Department of General and Oncological Surgery-Surgery CThe Chaim Sheba Medical CenterRamat GanIsrael
  2. 2.Department of SurgeryTel Aviv-Sourasky Medical Center IsraelTel AvivIsrael
  3. 3.Department of Surgery-BThe Chaim Sheba Medical CenterRamat GanIsrael
  4. 4.Department of SurgeryRabin Medical CenterPetah-TikvahIsrael
  5. 5.Department of SurgeryAssaf Harofe Medical CenterTzrifinIsrael
  6. 6.Department of SurgerySoroka Medical CenterBeer ShevaIsrael
  7. 7.Department of SurgeryRambam Medical centerHaifaIsrael

Personalised recommendations